The generation and characterization of potentially therapeutic Aβ antibodies in mice: Differences according to strain and immunization protocol

Vaccine

Volumn 21, Issue 3-4, 2002, Pages 290-297

  Spooner, Edward T ^a   Desai, Roanak V ^a   Mori, Chica ^a   Leverone, Jodi F ^a   Lemere, Cynthia A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

A immunization; Alzheimer's disease; Intranasal; Vaccine

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-15]; ANTIBODY; EPITOPE; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN M; UNCLASSIFIED DRUG; ALLOANTIBODY; IMMUNOGLOBULIN G; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; EPITOPE MAPPING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNIZATION; MALE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; TIME; TRANSGENIC MOUSE; ANIMAL; ANTIBODY SPECIFICITY; C57BL MOUSE; DBA MOUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; IMMUNOTHERAPY; INFUSION; INTRANASAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; METABOLISM; MOUSE; PATHOPHYSIOLOGY;

ADMINISTRATION, INTRANASAL; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EPITOPES; IMMUNIZATION; IMMUNOGLOBULIN G; IMMUNOTHERAPY; INFUSIONS, PARENTERAL; ISOANTIBODIES; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; PEPTIDE FRAGMENTS;

EID: 0037073558     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00464-4     Document Type: Article

References (26)

1. Dickson D.W. The pathogenesis of senile plaques. J Neuropathol Exp Neurol. 56(4):1997;321-339.
2. Selkoe D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 399(Supp):1999;A23-A31.
3. Iwatsubo T., Mann D.M., Odaka A., Suzuki N., Ihara Y. Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in Down syndrome. Ann Neurol. 37:1995;294-299.
4. Lemere C.A., Blustzjan J.K., Yamaguchi H., Wisniewski T., Saido T.C., Selkoe D.J. Sequence of deposition of heterogeneous amyloid b-peptides and Apo E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis. 3:1996;16-32.
5. Dickson D.W., Lee S.C., Mattiace L.A., Yen S.-H.C., Brosnan C. Microglia and cytokines in neurological diseases, with special reference to AIDS and Alzheimer's disease. Glia. 7:1993;75-83.
6. McGeer P.L., McGeer E.G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev. 21:1995;195-218.
7. Schenk D., Barbour R., Dunn W.et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177.
8. Games D., Adams D., Alessandrini R.et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature. 373:1995;523-527.
9. Bard F., Cannon C., Barbour R. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 6(8):2000;916-919.
10. Weiner H.L., Lemere C.A., Maron R.et al. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol. 48(4):2000;567-579.
11. Lemere C.A., Maron R., Spooner E.T.et al. Nasal Aβ treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann N Y Acad Sci. 920:2000;328-331.
12. Tamura S.-I., Ito Y., Asanuma H.et al. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J Immunol. 149(3):1992;981-988.
13. Tamura S., Yajima A., Hatori E.et al. Effects of frequent intranasal administration of adjuvant-combined influenza vaccine on the protection against virus infection. Vaccine. 15(16):1997;1784-1790.
14. Barackman J.D., Ott G., O'Hagan T. Intranasal immunization of mice with influenza vaccine in combination with the adjuvant LT-R72 induces potent mucosal and serum immunity which is stronger than that with traditional intramuscular immunization. Infect Immun. 67(8):1999;4276-4279.
15. McCluskie M.J., Davis H.L. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol. 161(9):1998;4463-4466.
16. Janus C., Pearson J., McLaurin J.et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 408(6815):2000;979-982.
17. Morgan D., Diamond D.M., Gottschall P.E.et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408(6815):2000;982-985.
18. Abbas A.K., Murphy K.M., Sher A. Functional diversity of helper T lymphocytes. Nature. 383:1996;787-793.
19. Morokata T., Ishikawa J., Ida K., Yamada T. C57BL/6 mice are more susceptible to antigen-induced pulmonary eosinophilia than BALB/c mice, irrespective of systemic T helper 1/T helper responses. Immunology. 98:1999;345-351.
20. Baldridge J.R., Yorgensen Y., Ward J.R., Ulrich J.T. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine. 18(22):2000;2416-2425.
21. Davis H.L., Weeratna R., Waldschmidt T.J.et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen [published erratum appears in J Immunol 1999 Mar 1162(5):3103]. J Immunol. 160(2):1998;870-876.
22. Gluck U., Gebbers J.-O., Gluck R. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J Virology. 73(9):1999;7780-7786.
23. Dickinson B.L., Clements J.D. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun. 63(5):1995;1617-1623.
24. Chong C.M., Friberg M., Clements J.D. LT(R192G), a non-toxic mutant of the heat-labile enterotoxin of Esherichia coli, elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp. Vaccine. 16:1998;732-740.
25. Morris C.B., Cheng E., Thanawastien A., Cardenas-Freytag L., Clements J.D. Effectiveness of intranasal immunization with HIV-gp160 Env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT (R192G). Vaccine. 18:2000;1944-1951.
26. Belyakov I.M., Hel Z., Kelsall B. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med. 7(12):2001;1320-1326.